162
Participants
Start Date
March 21, 2023
Primary Completion Date
March 15, 2024
Study Completion Date
May 15, 2024
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
(A2) Glimepiride/Vildagliptin/Metformin
Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
(B2) Glimepiride/Vildagliptin/Metformin
Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
Centro de Investigación Médica Aguascalientes, Aguascalientes
Oaxaca Site Management Organization SC., Oaxaca City
Centro de Investigación y Avances Médicos Especializados, Cancún
Oncológico Potosino, San Luis Potosí City
Mérida Investigación Clínica, Mérida
Laboratorios Silanes S.A. de C.V.
INDUSTRY